sponsored
PatientsVille.com Logo

PatientsVille

Ketoderm Medical Research Studies

Up-to-date List of Ketoderm Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Ketoderm Medical Research Studies

Rank Status Study
1 Unknown  Optimizing the Treatment of Toenail Onychomycosis Using a New Transdermal Patch Combined With Terbinafine/Ketoconazole
Condition: Onychomycosis
Interventions: Drug: 3 mg terbinafine and 2 mg ketoconazole containing patch;   Drug: 6 mg terbinafine and 2 mg ketoconazole containing patch;   Drug: 8 mg terbinafine and 2 mg ketoconazole containing patch
Outcome Measures: Presented by pharmacokinetic data (drug plasma concentrations vs. time) or drug deposit amounts in feet nails.;   (1) Efficacy is evaluated 24 weeks after the start of treatment and will be recorded at baseline, 8-week, 16-week and 24-week.;   (2) Safety Monitoring
2 Recruiting 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: 177Lu-J591;   Drug: Ketoconazole;   Drug: Hydrocortisone;   Drug: 111In-J591
Outcome Measures: Proportion free of radiographically evident metastases at 18 months by CT and/or MRI scan of the abdomen and pelvis, chest x-ray or CT scan of the chest and bone scan;   PSA response rate
3 Recruiting Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Conditions: Ovarian Cancer;   Cancer of Ovary;   Cancer of the Ovary;   Ovary Neoplasms;   Primary Peritoneal Carcinoma
Intervention: Drug: Fenretinide/LXS + Ketoconazole
Outcome Measures: Phase 2: Progression Free Survival;   Phase 2: Overall Survival;   Phase 1: To determine the systemic toxicity profile of 4-HPR/LXS oral powder + ketoconazole;   Phase 2: Event Free Survival;   Pharmacokinetics
4 Recruiting Ketoconazole as Inhibitor of the Enzyme CYP17 in Locally Advanced or Disseminated Granulosa Cell Tumour of Ovary
Condition: Granulosa Cell Tumour of the Ovary
Intervention: Drug: Ketoconazole
Outcome Measures: Overall response rate;   Clinical benefit;   Progression-free survival;   Overall survival;   Quality of life;   Safety profile
5 Available Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
Conditions: Recurrent Neuroblastoma;   Neuroblastoma
Interventions: Drug: Fenretinide Lym-X-Sorb Oral Powder;   Drug: Ketoconazole
Outcome Measure:
6 Not yet recruiting ITT-5 Mechanisms of Spermatogenesis
Condition: Gonadotropin Deficiency
Interventions: Drug: Testosterone 1% Gel;   Drug: Acyline;   Drug: Dutasteride;   Drug: Ketoconazole;   Drug: HCG;   Drug: placebo dutasteride;   Drug: placebo ketoconazole
Outcome Measures: Sperm concentration;   IT steroid concentration
7 Recruiting Calcitriol, Ketoconazole, and Hydrocortisone in Treating Patients With Advanced or Recurrent Prostate Cancer
Condition: Prostate Cancer
Interventions: Dietary Supplement: calcitriol;   Drug: ketoconazole;   Drug: therapeutic hydrocortisone
Outcome Measures: Maximum tolerated dose of calcitriol (phase I);   Prostate-specific antigen response rate (complete and partial) (phase II);   Toxicity as measured by NCI CTC version 3.0;   Objective tumor response as measured by monthly physical exam and radiographic evaluation every 12 weeks
8 Recruiting A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: ABT-199;   Drug: Ketoconazole
Outcome Measures: Determination of maximum observed plasma concentration (Cmax), time to Cmax (peak time, Tmax), terminal phase elimination rate constant (beta), terminal phase elimination half-life (t1/2), & area under the plasma concentration-time curve (AUC) of ABT-199;   Number of subjects with adverse events;   Percentage of subjects with adverse events;   Change in physical exam finding, including vital signs;   Change in clinical laboratory test results;   Change in cardiac assessment findings
9 Recruiting Phase 1 Pharmacokinetics Study of Oral IXAZOMIB in Patients With Advanced Nonhematologic Malignancies or Lymphoma
Conditions: Nonhematologic Malignancies;   Lymphoma
Interventions: Drug: IXAZOMIB Capsule B formulation;   Drug: IXAZOMIB Capsule A formulation;   Drug: ketoconazole;   Drug: rifampin
Outcome Measures: Arm 1: Ratio of geometric mean Cmax and AUC0-tlast of IXAZOMIB administered as Capsule B formulation with ketoconazole versus when administered as a single agent and 90% confidence intervals (CI);   Arm 2: Ratio of geometric mean Cmax and AUC0-tlast of Capsule B formulation versus Capsule A formulation and 90% CI;   Arm 3: Capsule B formulation ratio of geometric mean Cmax and AUC0-tlast of IXAZOMIB administered as Capsule B formulation with food versus without food and 90% CI;   Arm 4: Ratio of geometric mean Cmax and AUC0-tlast of IXAZOMIB administered as Capsule B with rifampin versus when administered as a single agent and 90% confidence intervals (CI);   Adverse events, serious adverse events, assessments of clinical laboratory values, and vital sign measurements;   Measures of disease response according to standard criteria
10 Unknown  Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
Conditions: Candidiasis;   Bacterial Vaginosis
Interventions: Drug: Clindamycin 100mg and Ketoconazole 400mg;   Drug: Tetracycline 100mg and Amphotericin B 50mg
Outcome Measures: Efficacy based on cure rate evaluated by clinical and laboratory criteria.;   Tolerability based on adverse events reports and patient's information;   Safety based on adverse events reports and laboratory criterion
11 Unknown  Biomarkers in Bone Marrow and Blood Samples From Patients With Prostate Cancer Treated With Ketoconazole
Condition: Prostate Cancer
Interventions: Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: protein analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: mass spectrometry
Outcome Measures: Progression-free survival (PFS) of men treated with ketoconazole;   At least 30% decline in PSA from baseline;   Overall survival
12 Recruiting Assessment of the Treatment of Severely Burned With Anabolic Agents on Clinical Outcomes, Recovery and Rehabilitation
Condition: Burns
Interventions: Procedure: Stable Isotope Infusion Study;   Procedure: Collection of blood and tissues;   Procedure: Radiology testing: Dual-energy X-ray absorptiometry (DEXA), K+ counter, ultrasound, MRI;   Drug: Humatrope;   Drug: Ketoconazole;   Drug: Oxandrolone;   Drug: Propranolol;   Drug: Oxandrolone and propranolol combined;   Drug: Humatrope and propranolol combined;   Drug: Placebo;   Behavioral: Exercise--Hospital supervised intensive exercise program;   Behavioral: Home exercise program
Outcome Measure: Outcome assessments will include measures of muscle wasting, weakness, immunosuppression chronic bone loss and decreased growth with increases in metabolic, hemodynamic, inflammatory and scarring responses.
13 Recruiting N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: fenretinide lipid matrix;   Drug: ketoconazole;   Other: laboratory biomarker analysis;   Other: pharmacological study
Outcome Measures: Maximum tolerated dose a;   Toxicity;   Plasma pharmacokinetics of 4-HPR/LXS oral powder and its metabolites;   Tolerability of the combination of ketoconazole and 4-HPR/LXS oral powder;   Disease response;   Plasma level of 4-HPR/LXS oral powder in PBMC as a tumor cell surrogate tissue;   Plasma levels of 4-HPR/LXS oral powder when given in combination with ketoconazole
14 Recruiting Buprenorphine Disposition and Clinical Effects
Condition: Healthy
Interventions: Drug: Buprenorphine;   Drug: Rifampin;   Other: grapefruit juice;   Drug: Ketoconazole
Outcome Measure: Area under the plasma concentration-time curve (AUC) of BPN and metabolites
15 Recruiting A Study Of Oral PF-02341066, A c-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Systemic Anaplastic Large-Cell Lymphoma;   Neoplasms;   Anaplastic Lymphoma Kinase, Human;   NSCLC
Interventions: Drug: PF-02341066;   Drug: Rifampin;   Drug: Ketoconazole
Outcome Measures: To test the safety of PF-02341066 when taken by people who have cancer;   To assess how the body handles blood concentrations of PF-02341066;   To find the dose of PF-02341066 that should be used in future clinical trials;   Anti-tumor activity;   To assess how the body handles blood concentrations of PF-02341066 in the presence of another drug, rifampin;   To assess how the body handles blood concentrations of PF-02341066 in the presence of another drug, ketoconazole
16 Recruiting Treatment for Endogenous Cushing's Syndrome
Condition: Endogenous Cushing's Syndrome
Intervention: Drug: COR-003
Outcome Measure: Reduction in urinary free cortisol in patients with endogenous Cushing's Syndrome.
17 Recruiting Diagnosis and Treatment of Leishmanial Infections
Condition: Leishmaniasis
Intervention:
Outcome Measure:

These studies may lead to new treatments and are adding insight into Ketoderm etiology and treatment.

A major focus of Ketoderm research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Ketoderm